Advertisement

Reactions Weekly

, Volume 1730, Issue 1, pp 22–22 | Cite as

Alemtuzumab/ganciclovir

Viral infections and neutropenia: 11 case reports
Case report
  • 27 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective single center study involving 45 patients, who received alemtuzumab between 1 January 2003 and 31 October 2014, 11 paediatric patients were described, of whom one was female [specific ages not stated; not all sexes stated] were described, who developed Epstein-Barr virus post-transplant lymphoproliferative disorder (EBV-PTLD; 1 patient), BK virus infection (1 patient), cytomegalovirus (CMV) reactivation (4 patients), disseminated CMV infection (1 patient) and adenovirus infection (4 patients) during conditioning treatment with alemtuzumab [Campath]. Additionally, one patient with BK virus infection developed neutropenia during treatment with ganciclovir for CMV prophylaxis [dosages and routes not stated; not all times to reactions onsets and outcomes stated].

C...

Reference

  1. Cupit-Link MC, et al. EBV-PTLD, adenovirus, and CMV in pediatric allogeneic transplants with alemtuzumab as part of pretransplant conditioning: A retrospective single center study. Journal of Pediatric Hematology/Oncology 40: e473-e478, No. 8, Nov 2018. Available from: URL: http://doi.org/10.1097/MPH.0000000000001138 - USA

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations